GET DAILY SIGNALSPasithea Therapeutics (KTTA) Shows +5% Move on FDA Clearance for Phase 2 NF1 Study
Key Takeaways
- Pasithea Therapeutics (KTTA) is a clinical-stage biotechnology company advancing PAS-004, a next-generation oral macrocyclic MEK inhibitor, for neurofibromatosis type 1 (NF1) and other MAPK pathway-driven diseases.
- Over the trailing 30 days, KTTA shares moved from roughly $0.48 in early October to about $0.50 in early November, a net change of approximately +5%, though the period featured sharp swings, including a decline toward the $0.35–$0.40 range before a strong rebound.
- The standout catalyst was the U.S. Food and Drug Administration clearing the Investigational New Drug (IND) application for a Phase 2 study of PAS-004 in NF1-associated cutaneous neurofibromas (cNF).
- Q3 2026 financial results are expected in mid-November, with a consensus estimate of a loss of $0.21 per share.
- The sole covering analyst tracked by major data providers maintains a Buy rating with a $3.00 price target, though the stock remains high-risk as a pre-revenue clinical-stage company.
- For additional detail, explore Price Targets, Earnings, and Forecast pages for KTTA.
- Discover AI-driven trading ideas and signals by exploring Trending AI Robots.
Market Snapshot for KTTA
Pasithea Therapeutics trades on the Nasdaq as a micro-cap, clinical-stage biotechnology name with a market capitalization in the mid-teens of millions of dollars and a 52-week trading range of approximately $0.28 to $2.06. The stock has been notably volatile, reflecting its early-stage profile and sensitivity to clinical and regulatory news rather than fundamental earnings.
In the most recent sessions, shares climbed sharply after the company announced that the FDA had cleared its IND application for PAS-004 in NF1-associated cutaneous neurofibromas. That development reversed a multi-week decline that had pushed the stock to its lowest levels of the period. While the net 30-day change is modest on a percentage basis, intra-period swings have been substantial, underscoring the stock's high-beta, news-driven character. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Pasithea Therapeutics (KTTA) Business Overview
Founded in 2020 and headquartered in Miami Beach, Florida, Pasithea Therapeutics is focused on the research and development of treatments for psychiatric and neurological disorders. Its lead asset, PAS-004, is a next-generation macrocyclic oral MEK inhibitor designed for chronic dosing, with a long half-life and a flat pharmacokinetic profile that the company believes may support favorable long-term tolerability.
The company is evaluating PAS-004 in a Phase 1 trial in advanced cancer patients with MAPK pathway-driven solid tumors and in a Phase 1/1b trial in adults with NF1-associated plexiform neurofibromas. With the recent IND clearance, Pasithea can also pursue a Phase 2 study in NF1-associated cutaneous neurofibromas, an indication for which no FDA-approved systemic therapies currently exist. PAS-004 has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) and Fast Track and Rare Pediatric Disease designations for NF1-related plexiform neurofibromas. As a pre-revenue company, Pasithea's valuation is driven primarily by clinical milestones, regulatory progress, and its cash position.
Recent Developments for KTTA
The most significant recent event was the November 3, 2026 announcement that the FDA cleared Pasithea's IND for a randomized, placebo-controlled Phase 2 trial of PAS-004 in patients with NF1-associated cutaneous neurofibromas. The company has described this as the second indication for which it intends to seek regulatory approval and a potential multibillion-dollar market opportunity. A virtual key opinion leader event on NF1 treatment was scheduled for November 4, 2026, featuring physicians from UAB and Stanford.
Earlier in 2026, Pasithea reported updated interim safety and clinical activity data from its first-in-human solid tumor trial, amended its NF1 study protocol to add dose levels, and announced Fast Track, Rare Pediatric Disease, and ALS Orphan Drug designations. On the financial side, the company reported a second-quarter 2026 loss of $0.16 per share, in line with consensus. Analyst coverage remains limited; HC Wainwright maintains a Buy rating with a $3.00 price target, according to available data. From what I see, this regulatory progress stands out as a key milestone worth monitoring closely.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary near-term catalyst for Pasithea is its third-quarter 2026 earnings report, expected in mid-November, alongside commentary on clinical timelines and cash runway. Investors will also monitor the planned initiation of the Phase 2 cNF study and the interim NF1 data update the company has guided for the fourth quarter of 2026.
Additional factors to watch include dose-escalation and safety data from the ongoing Phase 1 solid tumor and Phase 1/1b NF1 trials, progress toward regulatory discussions, and any financing activity needed to fund continued development. Competitive dynamics in the MEK inhibitor space, regulatory decisions, and broader risk appetite for early-stage biotech names will also influence the stock. As with any clinical-stage company, outcomes remain uncertain, and development-stage setbacks or capital needs could materially affect the share price. I’m watching this closely as more data emerges.
Using AI Tools in Biotech Analysis
Tickeron operates a marketplace of hundreds of AI-powered trading bots that monitor and trade thousands of tickers across varying strategies, timeframes, and performance metrics. Only the top-performing and most relevant bots are surfaced in its curated Trending AI Robots section, which is designed to help traders filter through a broad universe of automated signals. Because these bots differ in approach, holding period, and risk profile, investors can compare strategies and track records before selecting tools that align with their own objectives. In my view, reviewing the featured robots as part of a broader research process can provide systematic, data-driven insights that complement traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KTTA in downward trend: 10-day moving average moved below 50-day moving average on September 30, 2026
The 10-day moving average for KTTA crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KTTA as a result. In 81 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for KTTA turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KTTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for KTTA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KTTA's RSI Indicator exited the oversold zone, 36 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where KTTA advanced for three days, in 141 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
KTTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.247) is normal, around the industry mean (3.104). P/E Ratio (-0.273) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. KTTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KTTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement